...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of stroke and cerebrovascular diseases: The official journal of National Stroke Association >Effect of tissue plasminogen activator dose and interval on stroke severity
【24h】

Effect of tissue plasminogen activator dose and interval on stroke severity

机译：组织纤溶酶原激活剂的剂量和间隔对卒中严重程度的影响

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The recent study by Sahlas et al in the Journal of Stroke and Cerebrovascular Diseases concluded that "the estimation of a patient's weight in the acute setting can lead to overcalculation of the tissue plasminogen activator dose, which is associated with poorer functional outcomes." However, this conclusion is not well supported by their study because the most severe ischemic stroke cases were the ones that were most likely not weighed, and this severity could have led to the increased mortality that was found and the majority of unweighed patients were actually given an underdose that was associated with better discharge outcomes, as explained below. First, the authors stated that patients were "routinely weighed if medically stable," which suggests that those who were not weighed were more critical. This was supported by the data, in which the National Institutes of Health Stroke Scale scores were 36.4% higher for unweighed patients than for unweighed patients at the time of admission.
机译：Sahlas等人在《中风与脑血管疾病杂志》上的最新研究得出的结论是：“在急性环境中估计患者的体重可能导致组织纤溶酶原激活剂剂量的过度计算，这与较差的功能预后有关。”但是，该结论并未得到他们的研究的充分支持，因为最严重的缺血性中风病例是最有可能不称重的病例，这种严重性可能导致发现的死亡率增加，并且大多数未称重的患者都得到了治疗。剂量不足与出院效果更好相关，如下所述。首先，作者指出，“如果医学稳定，则应定期称重患者”，这表明未称重的患者更为严格。数据支持了这一点，在入院时，美国国立卫生研究院卒中量表评分比未称重患者高36.4％。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号